Allergocrom

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Allergocrom

What is Allergocrom?

Allergocrom is a medicinal product designed to alleviate the symptoms of allergic reactions, specifically targeting allergic inflammation of the eyes (conjunctivitis) and the nasal mucosa (rhinitis). It belongs to a class of medications known as mast cell stabilizers.

Active Ingredient and Mechanism

The primary active substance in Allergocrom is sodium cromoglicate. Unlike many other allergy treatments that manage symptoms after they have developed, sodium cromoglicate works by stabilizing the membranes of mast cells. Mast cells are a type of white blood cell that plays a central role in the immune system's response to allergens.

When a person with allergies is exposed to a trigger—such as pollen, dust mites, or animal dander—mast cells typically release chemical mediators, including histamine. These mediators are responsible for the swelling, itching, redness, and increased mucus production associated with allergic reactions. By stabilizing these cells, Allergocrom prevents the release of these inflammatory substances, thereby reducing the severity of the allergic response.

Common Applications

Allergocrom is primarily utilized for the management and prevention of chronic allergic conditions. Because of its preventative nature, it is often used continuously during periods of high allergen exposure to maintain its protective effect. It is commonly indicated for:

  • Allergic Conjunctivitis: Addressing symptoms such as itchy, watery, or red eyes caused by seasonal or perennial allergens.
  • Allergic Rhinitis: Assisting in the management of nasal congestion, sneezing, and runny nose.

As a mast cell stabilizer, the medication is most effective when used consistently, as its full therapeutic effect may take several days or weeks to reach its peak.

Regulatory References

  1. NIH DailyMed

What side effects are possible with Allergocrom?

Possible side effects and safety information

The safety profile for Sodium Cromoglycate (Allergocrom) is defined by officially documented adverse reactions, their frequency classifications, and specific constraints, as published in government regulatory documents.

Frequency-Classified Adverse Reactions

The most frequently documented events are related to the site of application. Regulatory classifications include:

  • Common (may affect up to 1 in 10 to 1 in 100 people): Transient stinging, burning, or irritation at the application site (eye or nose); headache; cough; or pharyngeal irritation.
  • Uncommon (may affect up to 1 in 100 to 1 in 1,000 people): Nausea, dizziness, or dryness of the mouth or throat.
  • Rare (may affect up to 1 in 1,000 to 1 in 10,000 people): Hypersensitivity reactions.

System-Organ Class and Serious Reactions

Adverse effects are officially grouped across several systems, including Eye Disorders, Respiratory Disorders, Nervous System Disorders, and Immune System Disorders.

Regulatory documents also list rare but clinically significant Serious Adverse Reactions, which include severe Hypersensitivity Reactions (such as angioedema—swelling of the face or larynx) and Paradoxical Bronchospasm (worsening of breathing immediately following inhalation).

Safety Restrictions and Considerations

The medication is formally contraindicated in individuals with a known history of hypersensitivity to the active substance or any other component. Furthermore, official product monographs advise Caution when used in patients with pre-existing severe renal or hepatic impairment, acknowledging the role of these organs in the drug's elimination.

Overdose and Emergency Response

The official regulatory profile for an overdose of Sodium Cromoglycate (Allergocrom) emphasizes its limited systemic absorption following ocular, nasal, or oral administration. Due to this physiological factor, systemic toxicity is not expected, and regulatory documents consistently indicate a low potential for severe or life-threatening outcomes. This benign profile is directly linked to the drug's poor absorption, which prevents significant levels from entering the systemic circulation.

Documented Overdose Manifestations

No specific acute overdose syndrome is documented in official prescribing information. Regulatory authorities note that any symptoms following overexposure are anticipated to be nonspecific. No population-specific notes regarding acute overdose severity or management are explicitly detailed in official labeling.

Emergency Actions and Management

Individuals should seek emergency medical attention immediately for any suspected overdose. However, the specific regulatory guidance for this medication indicates that no action other than medical observation may be necessary. Management of symptoms is symptomatic and supportive, applied only if clinical signs appear. Medical supervision is required for monitoring the patient's condition. The official labeling does not specify a known antidote.

Therapeutic Uses of Allergocrom

What Allergocrom treats: Main Uses and Benefits

This medication is commonly used across therapeutic domains where additional symptomatic support is needed, primarily focusing on conditions characterized by inflammatory or irritative states. Its core therapeutic use is in the prophylactic management of conditions such as allergic conjunctivitis, allergic rhinitis, mild to moderate bronchial asthma, and certain systemic mast cell disorders.

The treatment addresses symptoms related to inflammatory or irritative states, including severe eye itching, nasal congestion, sneezing, and gastrointestinal discomfort. It helps address symptom clusters that may become disruptive, reflecting its role in maintaining functional stability. This support is particularly relevant in situations where symptoms create noticeable physiological strain, such as persistent itchy eyes and running nose caused by chronic or seasonal allergies.

This medication may be part of symptomatic management in clinical settings that involve acute or unstable symptom patterns. It provides supportive relief that contributes to improved comfort during periods of heightened symptoms, helping patients cope more steadily with symptom fluctuations and easing the overall symptom load. It is commonly used to help with addressing symptoms that become more disruptive during flare-ups.


Quick Fact: Symptomatic Relief Domains
Allergocrom is used for managing recurrent or episodic manifestations, providing supportive relief for symptoms that interfere with daily functioning, and contributes to easing the overall symptom load during allergic seasons.

Regulatory References

  1. NIH StatPearls overview on Cromolyn Sodium

Eligibility and Restrictions for Use

This section summarizes the official population eligibility and non-eligibility information for Allergocrom (Sodium Cromoglycate) based strictly on regulatory labeling. The rules for use vary depending on the specific product formulation (e.g., ophthalmic, nasal, or oral).

Eligibility Scope

Category Official Regulatory Statements
Populations for whom use is contraindicated Patients with known hypersensitivity or allergy to cromolyn sodium or any component of the formulation.
Age-related eligibility rules Nasal Spray: Not recommended for children under 2 years unless directed by a doctor. Ophthalmic Solution: Safety and effectiveness in children below the age of 4 years have not been established.
Pregnancy and lactation eligibility status Pregnancy Category B (US FDA). Use during pregnancy is generally advised only if clearly needed. Caution is exercised for nursing mothers as it is unknown if the drug is excreted in human milk.
Eligibility-related restrictions The ophthalmic solution is contraindicated for use while wearing soft (hydrophilic) contact lenses.
Condition-specific eligibility rules For the systemic (oral) form, consideration should be given to decreasing the dosage in patients with impaired renal or hepatic function due to the drug's excretion routes.

Connection to the overall eligibility profile: The regulatory profile primarily sets an absolute contraindication based on known hypersensitivity to the drug. Beyond this, eligibility is restricted by age minimums which differ across dosage forms, and conditional constraints apply based on physiological status (pregnancy, lactation) and specific patient actions, such as wearing soft contact lenses with the eye drop formulation.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information regarding the interaction profile of Allergocrom (Sodium Cromoglycate) primarily focuses on administration requirements due to the medicine’s negligible systemic absorption following topical (ophthalmic/nasal) use. Systemic drug-drug interactions, including those mediated by metabolic pathways like the CYP enzyme system, are not documented in official labeling for the topical forms, nor are interactions with food, alcohol, or herbal products.

Documented Administration Constraints

Interaction Type Requirement as Stated in Regulatory Labels
Drug–Drug (Local) Co-administration with other eye drops or eye ointments requires a minimum interval of 15 minutes between applications.
Excipient–Product Soft contact lenses must be removed before instillation and may not be reinserted for 15 minutes due to interaction with the preservative Benzalkonium chloride.

Population-Specific Interaction Notes

The FDA labeling for the systemic (oral) formulation of Sodium Cromoglycate documents a specific finding in animal reproductive studies: combining the drug with Isoproterenol increased the incidence of certain malformations in pregnant mice. This is a highly specific observation from an animal model, and no comparable systemic interactions are known for the topical solution.

Mechanism of Action

The drug sodium cromoglicate modulates signaling pathways associated with heightened cellular excitability, specifically within the immune and inflammatory systems.

Mast Cell Membrane Modulation

This domain covers the drug's primary action: modulating the physicochemical state of the mast cell membrane. This action restricts the signaling sequence preceding mast cell degranulation, the cellular release process of preformed inflammatory mediators.

Inhibition of Mediator Release

The action on mast cell membranes results in inhibition of release of pro-inflammatory chemical mediators, including histamine and leukotrienes. This early molecular modification influences downstream pathway activity by reducing mediator flux.

Mitigation of Cellular Reactivity

This pathway effect contributes to broader cellular regulation. Limitation of calcium ion influx, which is required for mast cell activation, facilitates pathway maintenance by mitigating heightened cellular reactivity.

Dosage and Administration Information

The administration of Allergocrom (Sodium Cromoglycate) is defined by the pharmaceutical form, with specific requirements for route, dosing, and preparation. Its use follows a prophylactic pattern, requiring administration at regular intervals to maintain sustained effect.

For the Oral Solution, the 100 mg concentrate ampules must be diluted in a glass of water before intake. The standard adult dose is 200 mg four times daily, with specific timing required: doses must be taken 30 minutes before meals and at bedtime. The dose may be increased if a satisfactory response is not achieved within two to three weeks. Conversely, the dose should be decreased in patients with decreased renal or hepatic function. If a dose is missed and it is almost time for the next scheduled dose, the missed dose must be skipped.

Topical Ophthalmic administration involves instilling 1 to 2 drops into each eye, typically 4 to 6 times per day. Patients using the ophthalmic solution must refrain from wearing soft contact lenses during treatment. Inhaled forms (nebulized or MDI) are also generally administered four times daily, or 10 to 15 minutes before anticipated exposure to precipitating factors such as exercise.

These instructions define how the drug is prepared, scheduled, and applied based on the intended site of action, forming a standardized, non-advisory protocol for use.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Allergocrom


Evidence Base for Allergic Eye Conditions (Ophthalmic Use)

Research exploring the eye drops formulation of Allergocrom has been explored primarily through Randomized Controlled Trials (RCTs) and systematic reviews. These trials were used in research exploring how symptoms change over time, such as those related to seasonal allergies. Researchers examined patient-reported outcomes describing perceived discomfort like eye itching and tearing, alongside the assessment of visible physical signs. Studies included adults, adolescents, and children experiencing seasonal allergic conjunctivitis.

Studies exploring how symptoms change over time documented measurements of the difference in outcomes related to eye discomfort when the active drug was compared to a placebo. Research identified a limitation in the short follow-up durations, typically covering only a single pollen season. Long-term outcomes extending beyond this are not well characterized, and available data show patterns related to methodological heterogeneity (differences in study design) across trials.

Research Landscape for Allergic Nose Conditions (Nasal Use)

The nasal spray formulation was evaluated in controlled studies, including RCTs, which compared it to inactive placebos. These studies monitored outcomes related to physiological strain or stress. Research reports that outcomes evolved in observed populations, which included both adults and pediatric populations (studied in patients aged 2 years and older) with seasonal and perennial allergic rhinitis. Findings describe patterns related to outcomes measured for rhinitis symptoms, such as sneezing and congestion.

One key aspect that remains uncertain relates to how results seen in controlled settings translate to daily life. Due to the required frequent daily use, there is limited information on how well participants comply with the regimen in long-term observational settings, which may influence real-world outcomes. While the drug was studied for short- to intermediate-term relief, long-term effects are not fully established.

What Research Gaps and Uncertainties Remain

For the ophthalmic and nasal solutions, while short-term findings are available, the long-term effects are not fully established. For the inhaled solution (used in asthma), the evidence certainty has been described as low. Systematic reviews indicate that evidence quality varies across studies, noting that sample sizes were modest in many of the primary trials. A documented suspected publication bias was noted in some areas, which may contribute to uncertainty about the overall findings.

Frequently Asked Questions (FAQ)

Common questions about Allergocrom (FAQ)

Q: How often do people typically need to use Allergocrom for it to achieve its full effect?

Regulatory documents indicate that the medication requires consistent use over time because it functions preventatively. While initial symptomatic improvement is often observed within two to three days, in some cases, a period of up to six weeks may be needed to achieve the full desired response. The drug’s benefit relies on maintaining a regular administration schedule.

Q: What happens if I miss a scheduled application of Allergocrom for one day?

Official administration instructions emphasize that the effect of the medicine relies on administration at regular intervals to maintain its preventative action. For the oral formulation, regulatory guidance indicates that a missed dose is generally skipped if it is almost time for the next scheduled dose.

Q: Can Allergocrom be used to help with irritated or itchy eyes as well as nasal symptoms?

Yes, the active ingredient in Allergocrom is available in different formulations designed for different uses. The drug is produced as an ophthalmic solution (eye drops) for allergic eye conditions and as a nasal spray for allergic nose conditions. Each form has distinct instructions for use.

Q: Why is Allergocrom not typically prescribed for immediate, acute allergic reactions?

The general purpose of Allergocrom is described in official documents as prophylactic (preventative). Its mechanism of action works to stabilize mast cells, which prevents the release of inflammatory chemicals before a reaction starts, making it a treatment for ongoing management rather than immediate symptom relief.

Q: Does Allergocrom start working immediately, or does it require a period of build-up in the system?

Official information classifies this medication as a prophylactic agent that requires administration at regular intervals. Symptomatic improvement is usually evident only after a few days of starting treatment.

Q: Are there specific side effects more commonly reported when children use Allergocrom?

Available official information suggests that for children over the minimum approved age, the medication is not expected to cause side effects or problems that differ from those experienced by adults. Side effect reporting for all age groups focuses on events like irritation at the application site or uncommon symptoms like dizziness.

Q: Why is it often suggested to begin using Allergocrom before the start of the allergy season?

Because the drug's primary function is prophylactic (preventative), it must be used to establish its effect before a person is fully exposed to seasonal allergens. This allows the stabilization of the immune cells to occur prior to the onset of the allergy season for better management of symptoms.

Q: Is Allergocrom approved for treating conditions besides allergic rhinitis (hay fever)?

Regulatory documents confirm the drug is approved for use in other allergic conditions, including allergic eye conditions (ophthalmic solution) and certain forms of asthma (inhalation solution). The systemic (oral) formulation may be indicated for use in other conditions such as mastocytosis.

Q: Is Allergocrom effective for pet allergies, or only seasonal hay fever?

Research evidence has examined outcomes related to both seasonal allergies (like pollen) and perennial (year-round) allergic rhinitis. Perennial allergic rhinitis typically includes allergic reactions to indoor triggers such as dust mites or pet dander.

Q: Are there any major food or drink restrictions while using Allergocrom?

For the topical forms (eye drops and nasal spray), official labeling does not document systemic interactions with food, alcohol, or herbal products due to the medicine's local action. However, there are specific requirements that the concentrate is mixed only with water for administration.

Q: Is drowsiness or tiredness a commonly reported side effect of Allergocrom?

The list of common side effects in the official product information does not include general drowsiness or tiredness. Dizziness is listed, but only as an uncommon side effect, meaning it may affect up to 1 in 100 people.

Q: How long can a person safely continue to use Allergocrom, according to official information?

Official guidance indicates that treatment is generally continued for as long as needed to sustain symptomatic improvement. However, for some formulations, such as the ophthalmic solution, the official monograph advises against continuous use for more than 14 days without consulting a medical professional.

Q: Is Allergocrom available as a generic medication?

The active ingredient in Allergocrom is Sodium Cromoglycate, also known as Cromolyn Sodium. This name represents the internationally recognized generic name (INN) for the drug compound.

Q: Is Allergocrom available over-the-counter, or does it require a prescription?

The prescription status varies by the formulation and regional regulatory body. The ophthalmic solution generally requires a prescription, while the nasal spray formulation may be available for purchase without a prescription in some locations.

Q: Are there known interactions between Allergocrom and over-the-counter cold and flu medicines?

Official labeling for the topical forms (eye and nasal) does not document systemic drug-drug interactions with other medicines. Official guidance includes informing a healthcare professional about all medications being used, including any over-the-counter products.

Q: Is there research evidence suggesting Allergocrom is helpful for year-round, non-seasonal allergies?

Yes. Controlled studies and research reports have examined outcomes in populations with both seasonal and perennial (year-round) allergic rhinitis. This research includes data monitoring symptoms related to year-round allergic triggers.

Q: Is it generally considered safe to use Allergocrom while taking blood pressure medication?

The official regulatory labeling for the topical forms (eye drops and nasal spray) does not document systemic drug-drug interactions with other medications.

Q: What are the general guidelines if a person accidentally uses more than the recommended amount of Allergocrom?

Official documents state that overdosage is very unlikely with the typical topical or inhalation formulations. In the event of accidental ingestion of larger amounts, official guidance describes the management of overdosage as involving general symptomatic treatment.

Q: Are there official statements about operating machinery or driving while using Allergocrom?

Yes, official leaflets advise caution. Instillation of the eye drops may cause a temporary blurring of vision. Official leaflets advise that patients should refrain from driving or operating machinery until their vision has returned to normal.

Q: Are there documented cases of tolerance, dependence, or addiction associated with Allergocrom use?

Official regulatory documents defining the safety profile and adverse reactions of the drug do not list cases of tolerance (reduced effect over time), physical dependence, or addiction.

Q: Does the effectiveness of Allergocrom diminish or decrease after long-term use?

Research evidence indicates that studies exploring long-term outcomes and effects extending beyond short-term use are not fully characterized. Therefore, the available data is not fully sufficient to characterize whether effectiveness diminishes over periods of long-term continuous use.

Q: Is weight gain listed as a potential side effect of Allergocrom?

Weight gain is not listed as a commonly, uncommonly, or rarely reported side effect in the official regulatory product documents or monographs defining the drug's safety profile.

Q: Does Allergocrom contain any preservatives or inactive ingredients that might cause irritation?

Official labeling for the ophthalmic solution confirms the inclusion of the preservative Benzalkonium chloride. This inactive ingredient has been reported to cause eye irritation, and its presence necessitates the removal of soft contact lenses during administration.

Q: Are there differences between the nasal spray and eye drop versions of Allergocrom?

Yes, the medicine is available in several different formulations including an ophthalmic solution (eye drops) and a nasal spray. Each version is intended for a specific site of action and has distinct conditions for use and administration instructions.

Q: Does Allergocrom interact with common dietary supplements or vitamins?

Official labeling for the topical forms does not document systemic interactions with herbal products or supplements. Official guidance includes informing a healthcare professional about all supplements and vitamins being used.

Q: Is the active ingredient in Allergocrom widely used and approved outside of the US/EU?

The active ingredient, Sodium Cromoglycate (INN), is the internationally recognized name for the compound. It is stated in product information to be available globally under various trade names.

Q: Is there a maximum amount of time Allergocrom can be used continuously?

For certain topical formulations, such as the ophthalmic solution, official guidance advises against continuous use for more than 14 days unless consultation with a medical professional is undertaken.

How should Allergocrom be stored and disposed of?

Storage and Disposal of Allergocrom

Allergocrom (cromolyn sodium ophthalmic solution) must be stored under specific environmental and container conditions to maintain stability and sterility.


Storage Requirements

Condition Regulatory Requirement
Temperature Store at controlled room temperature (e.g., 15 C to 30 C / 59 F to 86 F); do not freeze.
Protection Keep in the original outer carton and protect from light.
Integrity Keep the bottle tightly closed when not in use.
Child Safety Must be kept out of the sight and reach of children.
In-Use Shelf-Life Discard any remaining product after 4 weeks (28 days) of first opening.

Disposal

Unused or expired product must be disposed of in accordance with local requirements. The medicine should not be flushed down the drain unless specifically instructed by official labeling.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Allergocrom found in:

A-Z Index: